Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nutritional High International Inc. Ordinary Shares SPLID

High Fusion Inc is engaged in the manufacturing, processing, and distribution of infused edible products. The company's operating and geographical segments include Palo Verde; Pasa Verde; Oregon; Colorado; Nevada and Washington. It generates maximum revenue from the Palo Verde segment.


OTCPK:SPLID - Post by User

Comment by Greedeon Jan 31, 2018 2:40pm
91 Views
Post# 27473132

RE:If you believe in EAT you have to Buy CHV!

RE:If you believe in EAT you have to Buy CHV!What about their $14m in losses or so?
JohnMiera wrote:
CHV Sp is .46 Trading. Cultivation license already with sales license on the way! Canada House Wellness Group Inc
 
User image
 
CHV have 3 divisions with (11) clinics and additional 4 more soon, growing, and tech which are Marijuana for Trauma Cannabis Wellness Clinics, Abba Medix Corp. Licensed Producer and Knalysis Technologies Data Analytics.
 
Marijuana for Trauma Cannabis Wellness Clinics provide services to its clients include:
 
• Documentation of a client’s medical history and current condition;
 
• Evaluation of their current condition and meds taken;
 
• Discussion of possible cannabis alternatives to consider;
 
• Assistance in obtaining a medical cannabis prescription;
 
• Assistance in identifying a “best fit” cannabis strain and vendor selection;
 
• Evaluation of treatment results, with the objective of establishing each client’s optimum benefit routine; and
 
• Counseling on how a client can take full advantage of any insurance and disability benefits that may be available.
 
Abba Medix Craft Cannabis Licensed Producer: Abba projects that it will complete its required two grow cycles and will have received its License to Sell and be fully operational by the end of Q2 2018, at a cost of approximately $5 million, a significant portion of which is already in place.
 
Abba will then offer a fully integrated seed to sale vertical with the benefit of an API that will link directly to the Cannabis Patient Management patient services and software provided by its sister company, Marijuana for Trauma – now with more than 7,000 active clients.
 
They have been issued permits from Health Canada and the Canadian Food Inspection Agency to import its selected starting genetics.
 
These genetics are scheduled to arrive in February. Abba looks to have two lots of cannabis harvested and ready for Health Canada approval by the end of June and anticipates receiving a License to Sell by July. Abba then expects to be in full production by September of this year.
 
At full production, Abba’s current grow operations are projected to produce more than 2,100 kg annually.
 
Knalysis Technologies Data Analytics: It created its smartphone Wellness Tracker to provide an essential treatment-results-treatment refinement feedback loop to refine its data sets.
 
For its sister company, MFT, it created its HIPPA-compliant Cannabis Patient Management software that seamlessly links MFT with its patients, physicians, and other care providers, a global approach to reporting, monitoring and care. Its leadership team envisioned a need for health technology connecting every aspect of the medical marijuana field, and has pioneered software developed to deliver better monitoring of symptoms, moods, and treatments for both physician and patient. Knalysis principals are industry veterans in technology, data collection, business applications, and the medical marijuana vertical
 
Has more than 12,000 medical cannabis patients on its software platforms representing 6% of the registered base in all of Canada. Coupled with Knalysis’ US client base, more than 32 million data points for medical cannabis treatment have been captured to date.
 
As patient count in the Knalysis platforms continues to increase by approximately 2,500 per month, it is now seeing the impact of having big data at its fingertips.
 
Knalysis is also gaining traction with several potential new cannabis clinic clients which would add another 10,000 – 20,000 patients into its platforms by mid-year, adding 10s of millions more data points for the benefit of its analytics subscribers.
 
CHV also expects license to sell, and applied for extraction license.


<< Previous
Bullboard Posts
Next >>